follow ep beat sale forecast lower opex modestli
increas non-gaap ep updat ep y/i in-
line abbvi guidanc rang increas outer-year ep
driven mix higher sale imbruvica humira coupl impact
share buy-back assumpt see overal came away call
encourag abbvi humira may absorb worst eu biosimilar
impact suggest upsid yearli brand eros forecast
see forecast ep growth follow three year
doubl digit growth ep trough post us humira biosimilar
share volatil believ setup improv given clariti eu
biosimilar humira price attract valuat catalyst includ four
product launch multipl clinical/regulatori readout reiter buy revis po
reflect emphasi dcf reflect humira loe see page
takeaway call
takeaway eu humira biosimilar management frame biosimilar discount
high end plan rang discount rang depend
countri base management disclosur estim affect eu market
averag discount rang assum intern
market impact biosimilar view import
biosimilar gross profit margin like given humira brand price
alreadi low estimate management commentari ex-u eros
moder seem plausibl assum biosimilar supplier rational
suppli given eu humira biosimilar market competit
onset wed expect front-load impact price versu enbrel analog
second biosimilar emerg post market format
outlook management express confid achiev doubl digit ep growth
absorb impact eu biosimilar competit humira invest new
launch difficult hcv hepat portflio ramp forecast hcv sale
y/i reflect assumpt stabl share patient volum
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
research-bas global pharmaceut
busi spun abbott
develop market drug area
immunolog virolog oncolog
buy thesi base street
underappreci strength humira
formul patent combin patent
litig timelin give us confid
see us biosimilar
optimist commerci potenti
next-gener immunolog agent
signific negoti leverag biosimilar
develop think like lead
patent settlement push biosimilar
launch
po valuat methodolog chang
new po reflect valuat methodolog weight dcf
dcf pe multipl vs prior assum termin
growth rate vs prior given humira loe loss-of-exclus new
price-to-earnings multipl vs prior reflect recent move comp
price object po base blend valuat risk-adjust dcf
price-to-earnings multipl non-gaap ep estim base ep growth
profil assum wacc termin growth rate believ dcf
assumpt reason minim contribut pipelin
valid late-stag clinic studi histor trade discount
peer price-to-earnings owe humira biosimilar risk
downsid risk earlier-than-anticip launch humira biosimilar us
clinic pipelin failur
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
